Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
01:16pm, Tuesday, 14'th Jan 2025
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
5 Biotech Stocks Worth Adding to Your Portfolio in 2025
11:06am, Tuesday, 14'th Jan 2025
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid p
Exelixis Provides Preliminary 2024 Results and Outlook for 2025
11:41am, Monday, 13'th Jan 2025
EXEL reports preliminary 2024 revenues. The company also provides guidance for 2025 and other pipeline updates.
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
10:46am, Monday, 13'th Jan 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2024, provided financial guidance for fiscal year 2025 a
The Best Defensive Stocks To Hedge Against Market Uncertainty
05:29pm, Friday, 10'th Jan 2025
2025 has kicked off with an air of uncertainty as investors wait to see how Donald Trump's economic agenda will impact inflation. A potential bear market presents opportunities to reassess portfolios
FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib
02:45pm, Friday, 10'th Jan 2025
EXEL's sNDA seeking approval of cabozantinib for the treatment of pancreatic neuroendocrine tumors will not be discussed at an ODAC.
Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza
04:19pm, Thursday, 09'th Jan 2025
Exelixis' stock has surged over 45% since my "Sell" rating given in March last year, driven by strong performance of cabozantinib, which remains a leading TKI for various cancers. Despite concerns ove
No FDA advisory meeting for Exelixis a positive, says Citi
12:16pm, Thursday, 09'th Jan 2025
Citi keeps a Buy rating on Exelixis with a $38 price target after the company announced that it has been notified by the FDA that the application for Cabometyx for the treatment of previously treated
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that the supplemental New Drug Application (sNDA) fo
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
04:05pm, Monday, 06'th Jan 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview
Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?
02:50pm, Monday, 06'th Jan 2025
EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about the stock as we believe there is room for further growth.
EXEL vs. INCY: Which Stock Should Value Investors Buy Now?
12:41pm, Wednesday, 25'th Dec 2024
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Incyte (INCY). But which of these two stocks is more attractive to value investo
Exelixis downgraded to Market Perform from Outperform at BMO Capital
04:15pm, Thursday, 19'th Dec 2024
BMO Capital downgraded Exelixis to Market Perform from Outperform with a price target of $40, up from $36. The "main driver of our thesis has played out positively," as a judge ruled in the MSN II lit
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
02:25pm, Thursday, 19'th Dec 2024
Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundament
